218 related articles for article (PubMed ID: 9645441)
21. Can CD10 be used as a diagnostic marker in thyroid pathology?
Yegen G; Demir MA; Ertan Y; Nalbant OA; Tunçyürek M
Virchows Arch; 2009 Jan; 454(1):101-5. PubMed ID: 19031085
[TBL] [Abstract][Full Text] [Related]
22. Comparison of intraoperative cytology with frozen sections in the diagnosis of thyroid lesions.
Tworek JA; Giordano TJ; Michael CW
Am J Clin Pathol; 1998 Oct; 110(4):456-61. PubMed ID: 9763031
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions.
Herrmann ME; LiVolsi VA; Pasha TL; Roberts SA; Wojcik EM; Baloch ZW
Arch Pathol Lab Med; 2002 Jun; 126(6):710-3. PubMed ID: 12033961
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
Abd-El Raouf SM; Ibrahim TR
Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
[TBL] [Abstract][Full Text] [Related]
25. [Low galectin-3 capacity to discriminate thyroid lesions].
De-León-Mazariegos R; Canedo-Patzi M; Pérez-Enríquez B; Candanedo-Gonzalez F; Saqui-Salces M; Gamboa-Domínguez A; Rull-Rodrigo JA
Rev Invest Clin; 2004; 56(5):623-8. PubMed ID: 15776867
[TBL] [Abstract][Full Text] [Related]
26. CD56, CD57, HBME1, CK19, Galectin-3 and p63 immunohistochemical stains in differentiating diagnosis of thyroid benign/malign lesions and NIFTP.
Tastekin E; Keskin E; Can N; Canberk S; Mut A; Erdogan E; Asa N; Güldiken S; Sezer A; Azatcam M
Pol J Pathol; 2019; 70(4):286-294. PubMed ID: 32146798
[TBL] [Abstract][Full Text] [Related]
27. Thyroglobulin synthesis of oxyphilic cells in various types of neoplastic and autoimmune thyroid diseases.
Hwang TS; Suh JS; Kim YI; Park SH; Cho BY; Koh CS
J Korean Med Sci; 1990 Mar; 5(1):33-7. PubMed ID: 1698387
[TBL] [Abstract][Full Text] [Related]
28. An immunohistochemical study of leu 7 and PCNA expression in thyroid neoplasms.
Fucich LF; Freeman SM; Marrogi AJ
Biotech Histochem; 1996 Nov; 71(6):298-303. PubMed ID: 8957557
[TBL] [Abstract][Full Text] [Related]
29. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
[TBL] [Abstract][Full Text] [Related]
30. Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules.
Trovato M; Villari D; Bartolone L; Spinella S; Simone A; Violi MA; Trimarchi F; Batolo D; Benvenga S
Thyroid; 1998 Feb; 8(2):125-31. PubMed ID: 9510120
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical diagnosis of papillary thyroid carcinoma.
Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid.
El Demellawy D; Nasr AL; Babay S; Alowami S
Pathol Res Pract; 2009; 205(5):303-9. PubMed ID: 19153015
[TBL] [Abstract][Full Text] [Related]
33. miRNA expression profiling of 'noninvasive follicular thyroid neoplasms with papillary-like nuclear features' compared with adenomas and infiltrative follicular variants of papillary thyroid carcinomas.
Borrelli N; Denaro M; Ugolini C; Poma AM; Miccoli M; Vitti P; Miccoli P; Basolo F
Mod Pathol; 2017 Jan; 30(1):39-51. PubMed ID: 27586203
[TBL] [Abstract][Full Text] [Related]
34. [Askenazi (Hurtle) cell tumors of the thyroid].
Raĭkhlin NT; Smirnova EA; Pavlovskaia AI; Rotin DL; Gurevich LE; Savelov NA
Arkh Patol; 2005; 67(6):13-6. PubMed ID: 16405013
[TBL] [Abstract][Full Text] [Related]
35. Bethesda classification is a valuable guide for fine needle aspiration reports and highly predictive especially for diagnosing aggressive variants of papillary thyroid carcinoma.
Evranos B; Polat SB; Baser H; Ozdemir D; Kilicarslan A; Yalcin A; Ersoy R; Cakir B
Cytopathology; 2017 Aug; 28(4):259-267. PubMed ID: 27666595
[TBL] [Abstract][Full Text] [Related]
36. GLUT1 glucose transporter expression in benign and malignant thyroid nodules.
Haber RS; Weiser KR; Pritsker A; Reder I; Burstein DE
Thyroid; 1997 Jun; 7(3):363-7. PubMed ID: 9226204
[TBL] [Abstract][Full Text] [Related]
37. CD56 expression in benign and malignant thyroid lesions.
Muthusamy S; Azhar Sha S; Abdullah Suhaimi SN; Kassim N; Mahasin M; Mohd Saleh MF; Md Isa N
Malays J Pathol; 2018 Aug; 40(2):111-119. PubMed ID: 30173227
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions.
Kim MJ; Kim HJ; Hong SJ; Shong YK; Gong G
Acta Cytol; 2006; 50(1):28-34. PubMed ID: 16514837
[TBL] [Abstract][Full Text] [Related]
39. Somatostatin receptor 2 expression determined by immunohistochemistry in cold thyroid nodules exceeds that of hot thyroid nodules, papillary thyroid carcinoma, and Graves' disease.
Sancak S; Hardt A; Singer J; Klöppel G; Eren FT; Güllüoglu BM; Sen LS; Sever Z; Akalin NS; Eszlinger M; Paschke R
Thyroid; 2010 May; 20(5):505-11. PubMed ID: 20450431
[TBL] [Abstract][Full Text] [Related]
40. [Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis].
He CN; He L; Cheng JQ; Chen SC; Zhao HF; Zhai JP; Zhang J
Zhonghua Bing Li Xue Za Zhi; 2008 Jan; 37(1):35-9. PubMed ID: 18509983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
